FXII (46C→T) polymorphism and in vivo generation of FXII activity. Gene frequencies and relationship in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 81, Issue 5, 1999, Pages 745-747

  Kohler, H P ^b   Futers, T S ^b   Grant, P J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; ENZYME PRECURSOR;

ADULT; ALLELE; ANGIOGRAPHY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION MAPPING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GENETICS; MIDDLE AGED; MUTATION;

BLOOD COAGULATION; CORONARY DISEASE; FACTOR XII; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC;

EID: 0033125184     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614565     Document Type: Article

References (11)

1. Revak SD, Cochrane CG, Johnston AR, Hugli TE. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-27.
2. Revak SD, Cochrane CG. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest 1976; 57: 852-60.
3. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Experimental Medicine 1978; 147: 719-29.
4. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
5. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction - Association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-8.
6. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
7. Kohler HP, Stickland MH, Ossei-Gerning N, Carter AM, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
8. Cool DE, MacGillivray RTA. Characterisation of the human blood coagulation factor XII gene. Intron/exon gene organisation and analysis of the 5′-flanking region. J Biol Chem 1987; 262: 13662-73.
9. Ford RP, Esnouf MP, Burgess AI, Sarphie A. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. J Immunoassay 1996; 17: 119-31.
10. Halbmayer WM, Haushofer A, Schön R, Mannhalter C, Strohmer E, Baumgarten K, Fischer M. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: Evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost 1994; 71: 68-72.
11. Halbmayer WM, Haushofer A, Radek J, Schön R, Deutsch M, Fischer M. Prevalence of factor XII (Hageman factor) deficiency among 426 patients with coronary heart disease awaiting cardiac surgery. Coronary Artery Disease 1994; 5: 451-4.